
  
    
      
        Introduction_NNP
        Infections_NNP with_IN resistant_JJ organisms_NNS represent_VBP a_DT serious_JJ
        menace_NN in_IN critically_RB ill_JJ patients_NNS ._. As_IN options_NNS for_IN effective_JJ
        chemotherapy_NN diminish_VB ,_, intensive_JJ care_NN unit_NN (_( ICU_NNP )_) mortality_NN
        will_MD increase_VB ._. Mortality_NNP rates_NNS as_RB high_JJ as_IN 60_CD %_NN have_VBP been_VBN
        reported_VBN for_IN serious_JJ infections_NNS (_( ventilator-associated_JJ
        pneumonia_NN [_NN VAP_NNP ]_NN ,_, bloodstream_NN infections_NNS )_) with_IN inappropriate_JJ
        initial_JJ treatment_NN [_NN 1_CD 2_CD 3_CD 4_CD 5_CD 6_CD ]_NN ._. In_IN a_DT recent_JJ study_NN [_NN 7_CD ]_NN
        ,_, inadequate_JJ antimicrobial_NN treatment_NN of_IN infection_NN was_VBD an_DT
        important_JJ and_CC independent_JJ determinant_NN of_IN mortality_NN in_IN
        critically_RB ill_JJ patients_NNS ._. In_IN that_DT series_NN patients_NNS receiving_VBG
        inadequate_JJ treatment_NN had_VBD an_DT in-hospital_JJ mortality_NN rate_NN of_IN
        52_CD ._. 1_LS %_NN ,_, as_IN compared_VBN with_IN 12_CD ._. 2_LS %_NN in_IN those_DT patients_NNS who_WP were_VBD
        adequately_RB treated_VBN ._.
        The_DT increasing_VBG prevalence_NN of_IN multiresistant_NN
        Gram-negative_NNP strains_NNS in_IN ICUs_NNP has_VBZ recently_RB rekindled_VBN
        interest_NN in_IN colistin_NN [_NN 8_CD 9_CD 10_CD 11_CD 12_CD ]_NN ,_, a_DT bactericidal_NN
        antibiotic_JJ that_WDT was_VBD used_VBN in_IN the_DT 1960_CD s_VBZ for_IN treatment_NN of_IN
        infections_NNS caused_VBN by_IN Gram-negative_NNP bacilli_NN ._. A_DT high_JJ
        incidence_NN of_IN adverse_JJ effects_NNS (_( nephrotoxicity_NN ,_,
        neurotoxicity_NN )_) ,_, along_IN with_IN the_DT development_NN of_IN newer_JJR
        effective_JJ drugs_NNS with_IN better_JJR safety_NN profiles_NNS ,_, resulted_VBD in_IN
        the_DT practical_JJ abandonment_NN of_IN systemic_JJ use_NN of_IN colistin_NN ,_,
        although_IN it_PRP still_RB remains_VBZ active_JJ 
        in_IN vitro_NN against_IN practically_RB all_DT
        strains_NNS of_IN 
        Pseudomonas_NNP aeruginosa_NN and_CC 
        Acinetobacter_NNP spp_NN ._. The_DT presence_NN of_IN
        multiresistant_NN 
        P_NN ._. aeruginosa_NN and_CC 
        Acinetobacter_NNP baumannii_NN strains_NNS in_IN
        our_PRP$ ICU_NNP prompted_VBD us_PRP to_TO try_VB treatment_NN with_IN colistin_NN as_IN a_DT
        last_JJ resort_NN in_IN patients_NNS with_IN serious_JJ infections_NNS with_IN such_JJ
        strains_NNS ._. Here_RB we_PRP report_VBP 3_CD years_NNS of_IN experience_NN with_IN
        intravenous_JJ colistin_NN in_IN the_DT treatment_NN of_IN Gram-negative_NNP
        sepsis_NN ._.
      
      
        Patients_NNS and_CC method_NN
        We_PRP studied_VBD critically_RB ill_JJ patients_NNS with_IN sepsis_NN caused_VBN by_IN
        Gram-negative_NNP bacilli_NN resistant_JJ to_TO all_DT antibiotics_NNS with_IN the_DT
        exception_NN of_IN colistin_NN ._. The_DT patients_NNS were_VBD treated_VBN in_IN a_DT
        six-bed_JJ ICU_NNP in_IN a_DT trauma_NN hospital_NN ._.
        Diagnosis_NNP of_IN infection_NN was_VBD based_VBN on_IN clinical_JJ data_NNS and_CC
        the_DT isolation_NN of_IN bacteria_NNS ,_, either_CC from_IN a_DT normally_RB sterile_JJ
        site_NN or_CC from_IN quantitative_JJ cultures_NNS of_IN tracheal_NN aspirate_NN or_CC
        bronchoalveolar_NN lavage_NN ._. More_RBR specifically_RB ,_, the_DT clinical_JJ
        prerequisites_NNS for_IN the_DT diagnosis_NN of_IN VAP_NNP were_VBD as_IN follows_VBZ :_:
        presence_NN of_IN at_IN least_JJS two_CD of_IN fever_NN (_( >_NN 38_CD ._. 3_LS °_NN C_NNP )_) ,_,
        leukocytosis_NNS or_CC leukopenia_NN ,_, and_CC purulent_NN bronchial_NN
        secretions_NNS ;_: and_CC a_DT new_JJ and_CC persistent_JJ infiltrate_VB on_IN chest_NN
        radiography_NN ._. On_IN isolation_NN of_IN strains_NNS of_IN 
        P_NN ._. aeruginosa_NN and_CC 
        A_DT ._. baumannii_NN that_WDT were_VBD resistant_JJ to_TO
        all_DT antibiotics_NNS apart_RB from_IN colistin_NN ,_, intravenous_JJ colistin_NN
        sulfomethate_NN sodium_NN (_( Colistin_NNP ;_: Norma_NNP ,_, Athens_NNP ,_, Greece_NNP )_) was_VBD
        initiated_VBN at_IN the_DT discretion_NN of_IN the_DT attending_VBG physician_NN ._. The_DT
        dosage_NN of_IN colistin_NN ,_, administered_VBN intravenously_RB ,_, was_VBD 3_CD MU_NNP
        three_CD times_NNS daily_JJ ,_, adjusted_VBN for_IN creatinine_NN clearance_NN [_NN 10_CD ]_NN
        ._.
        Susceptibility_NNP testing_NN was_VBD done_VBN using_VBG an_DT automated_VBN broth_NN
        microdilution_NN test_NN (_( Vitek_NNP ;_: bioMérieux_NN ,_, Durham_NNP ,_, NC_NNP ,_, USA_NNP )_) ._.
        The_DT breakpoints_NNS for_IN susceptibility_NN were_VBD those_DT recommended_VBN
        by_IN the_DT National_NNP Committee_NNP for_IN Clinical_NNP Laboratory_NNP
        Standards_NNP ._. Susceptibility_NNP to_TO colistin_NN was_VBD tested_VBN using_VBG the_DT
        disk_NN diffusion_NN method_NN ,_, with_IN a_DT 10_CD μg_NN colistin_NN disk_NN (_( Oxoid_NNP
        Ltd_NNP ,_, Basingstoke_NNP ,_, Hants_NNP ,_, UK_NNP )_) ._. Isolated_NNP bacilli_NN were_VBD
        considered_VBN susceptible_JJ if_IN the_DT inhibition_NN zone_NN was_VBD 11_CD mm_NN or_CC
        greater_JJR ._.
      
      
        Results_NNS
        In_IN all_DT ,_, 28_CD patients_NNS were_VBD treated_VBN with_IN colistin_NN ._. In_IN 16_CD
        cases_NNS colistin_NN was_VBD part_NN of_IN the_DT initial_JJ empiric_JJ regimen_NN
        based_VBN on_IN previous_JJ surveillance_NN cultures_NNS ,_, with_IN subsequent_JJ
        cultures_NNS confirming_VBG the_DT sensitivity_NN pattern_NN ._. For_IN the_DT
        remaining_VBG patients_NNS ,_, colistin_NN was_VBD introduced_VBN when_WRB culture_NN
        results_NNS became_VBD available_JJ in_IN those_DT who_WP had_VBD not_RB responded_VBN to_TO
        the_DT initial_JJ empiric_JJ regimen_NN ._. Four_CD of_IN the_DT 28_CD patients_NNS died_VBD
        within_IN 48_CD hours_NNS of_IN the_DT initiation_NN of_IN colistin_NN ;_: these_DT
        patients_NNS were_VBD not_RB included_VBN in_IN the_DT analysis_NN because_IN they_PRP
        were_VBD not_RB considered_VBN true_JJ therapeutic_JJ failures_NNS ._. Data_NNS on_IN the_DT
        remaining_VBG 24_CD patients_NNS are_VBP presented_VBN in_IN Table_NNP 1_CD ._. The_DT mean_JJ
        age_NN of_IN the_DT patients_NNS was_VBD 44_CD ._. 3_LS years_NNS and_CC the_DT mean_NN Acute_NNP
        Physiology_NNP and_CC Chronic_NNP Health_NNP Evaluation_NNP (_( APACHE_NNP )_) II_NNP score_NN
        was_VBD 20_CD ._. 6_CD ._. In_IN five_CD patients_NNS multiple_JJ organ_NN failure_NN was_VBD
        present_JJ at_IN the_DT initiation_NN of_IN colistin_NN ._. A_DT total_NN of_IN 26_CD
        courses_NNS of_IN colistin_NN were_VBD given_VBN ,_, for_IN the_DT following_JJ
        infections_NNS :_: VAP_NNP (_( 15_CD cases_NNS )_) ,_, empyema_NN thoracis_NNS (_( one_CD case_NN )_) ,_,
        post-traumatic_JJ meningitis_NNS (_( one_CD case_NN )_) ,_, sinusitis_NNS (_( one_CD case_NN )_) ,_,
        urinary_JJ tract_NN infection_NN (_( one_CD case_NN )_) ,_, catheter-related_JJ sepsis_NN
        (_( three_CD cases_NNS )_) ,_, and_CC sepsis_NN of_IN unknown_JJ primary_JJ origin_NN (_( four_CD
        cases_NNS )_) ._. The_DT offending_VBG pathogen_NN was_VBD 
        P_NN ._. aeruginosa_NN in_IN 20_CD cases_NNS and_CC 
        A_DT ._. baumannii_NN in_IN six_CD ._. In_IN six_CD cases_NNS a_DT
        co-pathogen_JJ was_VBD isolated_VBN ._. Median_JJ duration_NN of_IN treatment_NN with_IN
        colistin_NN was_VBD 13_CD ._. 5_LS days_NNS (_( range_NN 4_CD -_: 24_CD days_NNS )_) ._. In_IN all_DT cases_VBZ a_DT
        second_JJ antibiotic_JJ (_( ceftazidime_NN in_IN 16_CD ,_,
        piperacillin_NN /_NN tazobactam_NN in_IN six_CD ,_, and_CC a_DT carbapenem_NN in_IN four_CD
        cases_NNS )_) was_VBD added_VBN to_TO the_DT therapeutic_JJ regimen_NN ,_, despite_IN
        documented_VBN resistance_NN ._.
        Clinical_NNP response_NN ,_, judged_VBN as_IN abatement_NN of_IN fever_NN for_IN at_IN
        least_JJS 48_CD hours_NNS with_IN parallel_JJ improvement_NN in_IN vital_JJ signs_NNS ,_,
        was_VBD observed_VBN for_IN 17_CD of_IN the_DT 26_CD treatments_NNS ._. In_IN two_CD patients_NNS
        with_IN septic_JJ shock_NN (_( one_CD hypothermic_JJ and_CC the_DT other_JJ with_IN
        low-grade_JJ fever_NN )_) it_PRP was_VBD possible_JJ to_TO stop_VB vasopressors_NNS in_IN
        the_DT following_VBG 48_CD hours_NNS ,_, and_CC this_DT was_VBD also_RB considered_VBN proof_NN
        of_IN response_NN ._. Thus_RB ,_, clinical_JJ response_NN was_VBD seen_VBN for_IN 19_CD out_IN of_IN
        26_CD treatments_NNS with_IN colistin_NN (_( 73_CD %_NN )_) ._. Survival_NNP at_IN 30_CD days_NNS was_VBD
        57_CD ._. 7_CD %_NN ._.
        In_IN the_DT subgroup_NN of_IN patients_NNS with_IN bacteremia_NN (_( 11_CD
        patients_NNS )_) ,_, an_DT initial_JJ clinical_JJ response_NN to_TO colistin_NN was_VBD
        observed_VBN in_IN seven_CD patients_NNS and_CC the_DT ICU_NNP mortality_NN was_VBD 54_CD ._. 5_LS %_NN ._.
        Additional_JJ blood_NN culture_NN data_NNS after_IN initiation_NN of_IN colistin_NN
        were_VBD available_JJ in_IN two_CD of_IN the_DT clinical_JJ responders_NNS ,_, and_CC
        bacterial_JJ eradication_NN was_VBD confirmed_VBN in_IN both_DT ._. In_IN the_DT
        subgroup_NN of_IN patients_NNS with_IN VAP_NNP ,_, 11_CD out_IN of_IN 15_CD patients_NNS
        (_( 73_CD ._. 3_LS %_NN )_) had_VBD an_DT initial_JJ clinical_JJ response_NN to_TO colistin_NN ,_,
        bacterial_JJ eradication_NN was_VBD observed_VBN in_IN eight_CD (_( 53_CD ._. 3_LS %_NN )_) ,_, and_CC
        ICU_NNP mortality_NN was_VBD 40_CD %_NN ._.
        Three_CD patients_NNS had_VBD already_RB developed_VBN acute_JJ renal_JJ failure_NN
        at_IN the_DT initiation_NN of_IN treatment_NN with_IN colistin_NN and_CC were_VBD being_VBG
        treated_VBN with_IN continuous_JJ venovenous_JJ hemodiafiltration_NN
        (_( CVVHD_NNP )_) ._. None_NN of_IN them_PRP survived_VBD ._. The_DT other_JJ patients_NNS had_VBD a_DT
        serum_NN creatinine_NN below_IN 2_CD ._. 5_CD mg_NN /_NN dl_NN with_IN one_CD exception_NN (_( a_DT
        patient_NN with_IN serum_NN creatinine_NN 3_CD ._. 2_CD mg_NN /_NN dl_NN )_) ,_, and_CC all_DT had_VBD
        adequate_JJ diuresis_NNS ._. Only_RB patients_NNS 8_CD ,_, 17_CD and_CC 24_CD (_( 14_CD ._. 3_LS %_NN )_) had_VBD
        an_DT increase_NN in_IN serum_NN creatinine_NN of_IN greater_JJR than_IN 1_CD mg_NN /_NN dl_NN
        during_IN treatment_NN ,_, with_IN no_DT serious_JJ consequences_NNS in_IN patients_NNS
        8_CD and_CC 17_CD ._. Only_RB patient_NN 24_CD developed_VBN anuria_NN and_CC serious_JJ
        impairment_NN in_IN renal_JJ function_NN requiring_VBG CVVHD_NNP (_( Table_NNP 2_LS )_) ._.
        No_DT patient_NN developed_VBN clinically_RB apparent_JJ neuromuscular_NN
        transmission_NN blockade_NN ._.
      
      
        Discussion_NNP
        Colistin_NNP is_VBZ a_DT cationic_JJ polypeptide_NN antibiotic_NN of_IN the_DT
        polymyxin_NN family_NN that_WDT is_VBZ rapidly_RB bactericidal_NN to_TO
        Gram-negative_NNP bacteria_NNS ._. The_DT action_NN of_IN colistin_NN is_VBZ by_IN a_DT
        detergent-like_JJ mechanism_NN ,_, interfering_VBG with_IN the_DT structure_NN
        and_CC function_NN of_IN the_DT outer_JJ cytoplasmic_JJ membrane_NN of_IN bacteria_NNS
        and_CC resulting_VBG in_IN bacterial_JJ death_NN [_NN 11_CD 13_CD ]_NN ._. It_PRP is_VBZ
        administered_VBN as_IN colistin_NN sulfomethate_NN sodium_NN and_CC its_PRP$
        hydrolysis_NNS releases_VBZ the_DT active_JJ drug_NN ._. It_PRP is_VBZ removed_VBN by_IN
        glomerular_NN filtration_NN [_NN 10_CD ]_NN ._.
        Colistin_NNP remains_VBZ active_JJ 
        in_IN vitro_NN against_IN almost_RB all_DT strains_NNS
        of_IN 
        P_NN ._. aeruginosa_NN ,_, 
        Klebsiella_NNP pneumoniae_NN ,_, 
        Acinetobacter_NNP spp_NN ._. ,_, and_CC 
        Enterobacter_NNP spp_NN ._. On_IN the_DT other_JJ hand_NN ,_, 
        Proteus_NNP spp_NN ._. ,_, 
        Providencia_NNP spp_NN ._. ,_, 
        Serratia_NNP spp_NN ._. ,_, 
        Burkholderia_NNP cepacia_NN ,_, and_CC some_DT
        strains_NNS of_IN 
        Stenotrophomonas_NNP maltophilia_NN are_VBP
        usually_RB resistant_JJ to_TO colistin_NN [_NN 8_CD 9_CD 10_CD 11_CD 12_CD 13_CD 14_CD 15_CD 16_CD 17_CD
        18_CD ]_NN ._. Cross-resistance_NNP with_IN other_JJ antibiotics_NNS has_VBZ not_RB been_VBN
        reported_VBN [_NN 10_CD 13_CD ]_NN ,_, and_CC acquired_VBD resistance_NN is_VBZ rare_JJ [_NN 11_CD
        17_CD ]_NN ._. Although_IN lower_JJR susceptibility_NN rates_NNS for_IN 
        P_NN ._. aeruginosa_NN have_VBP been_VBN reported_VBN in_IN
        patients_NNS with_IN cystic_JJ fibrosis_NNS undergoing_VBG chronic_JJ
        prophylactic_JJ treatment_NN with_IN inhaled_JJ colistin_NN [_NN 18_CD ]_NN ,_, 81_CD %_NN
        of_IN strains_NNS of_IN 
        P_NN ._. aeruginosa_NN from_IN such_JJ patients_NNS are_VBP
        still_RB susceptible_JJ to_TO colistin_NN [_NN 14_CD ]_NN ._.
        With_IN regard_NN to_TO clinical_JJ efficacy_NN ,_, data_NNS are_VBP limited_JJ ._. In_IN
        the_DT 1960_CD s_VBZ the_DT drug_NN ,_, administered_VBN mostly_RB via_IN the_DT
        intramuscular_NN route_NN ,_, was_VBD found_VBN to_TO be_VB of_IN use_NN in_IN the_DT
        treatment_NN of_IN infections_NNS with_IN Gram-negative_NNP bacteria_NNS
        resistant_JJ to_TO other_JJ antibiotics_NNS ._. Response_NNP was_VBD better_JJR in_IN
        patients_NNS with_IN bloodstream_NN infections_NNS resulting_VBG from_IN urinary_JJ
        tract_NN infection_NN ._. Colistin_NNP was_VBD less_RBR effective_JJ in_IN patients_NNS
        with_IN osteomyelitis_NNS ,_, biliary_JJ tract_NN disease_NN ,_, endocarditis_NNS ,_,
        and_CC suppurative_JJ infections_NNS of_IN the_DT lung_NN (_( probably_RB because_IN of_IN
        suboptimal_NN concentrations_NNS locally_RB )_) ,_, and_CC it_PRP was_VBD ineffective_JJ
        in_IN the_DT treatment_NN of_IN Gram-negative_NNP infections_NNS in_IN neutropenic_JJ
        patients_NNS [_NN 10_CD 11_CD 13_CD ]_NN ._.
        In_IN recent_JJ years_NNS intravenous_JJ colistin_NN has_VBZ occasionally_RB
        been_VBN used_VBN in_IN acute_JJ exacerbations_NNS of_IN multiresistant_NN 
        P_NN ._. aeruginosa_NN in_IN patients_NNS with_IN cystic_JJ
        fibrosis_NNS [_NN 19_CD 20_CD 21_CD ]_NN ._. With_IN regard_NN to_TO adult_NN patients_NNS
        without_IN cystic_JJ fibrosis_NNS treated_VBN with_IN colistin_NN ,_, an_DT
        observational_NN study_NN [_NN 9_CD ]_NN reported_VBD a_DT clinical_JJ response_NN rate_NN
        of_IN 58_CD %_NN ._. In_IN that_DT study_NN the_DT drug_NN was_VBD used_VBN in_IN 59_CD patients_NNS with_IN
        serious_JJ infections_NNS with_IN 
        A_DT ._. baumannii_NN (_( 65_CD %_NN )_) and_CC 
        P_NN ._. aeruginosa_NN (_( 35_CD %_NN )_) resistant_JJ to_TO all_DT
        other_JJ antibiotics_NNS ._. Of_IN the_DT patients_NNS studied_VBN ,_, 65_CD %_NN were_VBD
        critically_RB ill_JJ and_CC the_DT mean_NN APACHE_NNP II_NNP score_NN was_VBD 13_CD ._. 1_LS ._.
        Response_NNP was_VBD suboptimal_NN (_( 25_CD %_NN )_) in_IN patients_NNS with_IN pneumonia_NN ._.
        Recently_RB ,_, Garnacho-_NNP Montero_NNP and_CC coworkers_NNS [_NN 12_CD ]_NN reported_VBD
        the_DT only_RB controlled_VBN study_NN of_IN colistin_NN in_IN patients_NNS without_IN
        cystic_JJ fibrosis_NNS ._. Patients_NNS with_IN VAP_NNP caused_VBN by_IN 
        A_DT ._. baumannii_NN were_VBD treated_VBN with_IN
        imipenem_NN (_( 21_CD patients_NNS )_) or_CC ,_, in_IN the_DT case_NN of_IN resistance_NN to_TO all_DT
        other_JJ antibiotics_NNS ,_, with_IN colistin_NN (_( 14_CD patients_NNS )_) ._. APACHE_NNP II_NNP
        scores_NNS at_IN presentation_NN and_CC Sequential_NNP Organ_NNP Failure_NN
        Assessment_NNP scores_NNS at_IN the_DT time_NN of_IN diagnosis_NN of_IN VAP_NNP were_VBD
        similar_JJ between_IN the_DT groups_NNS ._. Achieving_NNP clinical_JJ cure_NN in_IN 57_CD %_NN
        of_IN cases_NNS ,_, intravenous_JJ colistin_NN was_VBD as_RB effective_JJ as_IN
        imipenem_NN ._. No_DT significant_JJ difference_NN was_VBD observed_VBN between_IN
        the_DT two_CD groups_NNS in_IN terms_NNS of_IN crude_NN mortality_NN ,_, VAP_NNP attributed_VBD
        mortality_NN ,_, microbiologic_JJ cure_NN ,_, or_CC duration_NN of_IN ICU_NNP stay_VB ._.
        Limitations_NNPS of_IN that_DT study_NN are_VBP the_DT small_JJ number_NN of_IN patients_NNS
        included_VBD ,_, open_JJ design_NN ,_, and_CC lack_NN of_IN randomization_NN ._.
        Clinical_NNP response_NN in_IN the_DT present_JJ study_NN was_VBD somewhat_RB
        better_JJR than_IN in_IN the_DT study_NN conducted_VBN by_IN Levin_NNP and_CC coworkers_NNS [_NN
        9_CD ]_NN ,_, despite_IN a_DT higher_JJR mean_NN APACHE_NNP II_NNP score_NN ._. The_DT observed_VBD
        30_CD -_: day_NN mortality_NN rate_NN of_IN 42_CD ._. 3_LS %_NN in_IN the_DT present_JJ study_NN is_VBZ
        certainly_RB high_JJ but_CC not_RB unexpectedly_RB so_RB for_IN the_DT severity_NN of_IN
        illness_NN ._. Because_IN mortality_NN rates_NNS in_IN the_DT region_NN of_IN 50_CD -_: 60_CD %_NN
        have_VBP been_VBN reported_VBN in_IN critically_RB ill_JJ patients_NNS receiving_VBG
        inappropriate_JJ treatment_NN [_NN 1_CD 2_CD 3_CD 4_CD 5_CD 6_CD 7_CD ]_NN ,_, the_DT use_NN of_IN
        colistin_NN may_MD indeed_RB have_VB been_VBN of_IN clinical_JJ benefit_NN in_IN our_PRP$
        patients_NNS ._.
        Both_DT the_DT study_NN by_IN Levin_NNP and_CC coworkers_NNS [_NN 9_CD ]_NN and_CC a_DT study_NN
        of_IN an_DT experimental_JJ pneumonia_NN model_NN with_IN 
        Acinetobacter_NNP sp_NN ._. in_IN immunocompetent_NN
        mice_NNS [_NN 22_CD ]_NN suggest_VBP that_IN ,_, despite_IN good_JJ 
        in_IN vitro_NN activity_NN ,_, the_DT clinical_JJ
        efficacy_NN of_IN colistin_NN may_MD be_VB suboptimal_NN in_IN Gram-negative_NNP
        pneumonia_NN ._. On_IN the_DT other_JJ hand_NN ,_, Garnacho-_NNP Montero_NNP and_CC
        coworkers_NNS [_NN 12_CD ]_NN reported_VBD that_DT colistin_NN was_VBD not_RB inferior_JJ to_TO
        the_DT standard_JJ treatment_NN for_IN VAP_NNP caused_VBN by_IN 
        A_DT ._. baumannii_NN ,_, with_IN a_DT clinical_JJ cure_NN
        rate_NN of_IN 57_CD %_NN ._. Results_NNS were_VBD rather_RB better_JJR in_IN our_PRP$ patients_NNS
        with_IN VAP_NNP ,_, in_IN whom_WP a_DT clinical_JJ response_NN was_VBD seen_VBN in_IN 73_CD ._. 3_LS %_NN and_CC
        bacterial_JJ eradication_NN in_IN 53_CD ._. 3_LS %_NN ._. Perhaps_RB the_DT high_JJ doses_NNS of_IN
        colistin_NN used_VBN in_IN our_PRP$ study_NN were_VBD in_IN part_NN responsible_JJ for_IN
        this_DT ._.
        The_DT dosage_NN of_IN colistin_NN used_VBN in_IN our_PRP$ study_NN was_VBD more_RBR than_IN
        double_JJ that_IN usually_RB recommended_VBD [_NN 9_CD 10_CD 12_CD ]_NN ,_, although_IN much_RB
        higher_JJR doses_NNS -_: with_IN a_DT parallel_JJ increase_NN in_IN nephrotoxicity_NN -_:
        have_VBP been_VBN reported_VBN in_IN the_DT past_JJ [_NN 23_CD ]_NN ._. We_PRP opted_VBD for_IN the_DT
        higher_JJR dose_NN because_IN of_IN the_DT severity_NN of_IN the_DT infections_NNS being_VBG
        treated_VBN ._. A_DT recent_JJ study_NN that_WDT reported_VBD that_DT colistin_NN
        methanosulfate_NN is_VBZ less_RBR rapidly_RB bactericidal_NN than_IN is_VBZ
        colistin_NN in_IN 
        P_NN ._. aeruginosa_NN [_NN 14_CD ]_NN offers_VBZ
        retrospective_NN justification_NN for_IN the_DT higher_JJR dosage_NN used_VBN in_IN
        our_PRP$ ICU_NNP ._. It_PRP appears_VBZ that_IN peak_NN concentrations_NNS of_IN colistin_NN
        methanosulfate_NN 16_CD times_NNS the_DT minimum_JJ inhibitory_NN
        concentration_NN or_CC greater_JJR are_VBP required_VBN for_IN complete_JJ 
        in_IN vitro_NN killing_NN of_IN 
        P_NN ._. aeruginosa_NN within_IN 24_CD hours_NNS [_NN 14_CD ]_NN
        ._.
        In_IN the_DT present_JJ study_NN all_DT patients_NNS received_VBD a_DT β-lactam_JJ in_IN
        addition_NN to_TO colistin_NN ,_, despite_IN documented_VBN resistance_NN ._. In_IN
        some_DT cases_VBZ the_DT second_JJ drug_NN was_VBD added_VBN to_TO act_VB against_IN
        isolated_VBN co-pathogens_JJ ,_, but_CC in_IN most_JJS patients_NNS this_DT addition_NN
        indicated_VBD the_DT attending_VBG physician_NN 's_POS lack_NN of_IN confidence_NN in_IN
        monotherapy_NN with_IN colistin_NN ._. Although_IN combinations_NNS of_IN
        colistin_NN with_IN β-lactams_JJ are_VBP reported_VBN to_TO be_VB of_IN unproven_JJ
        benefit_NN [_NN 24_CD 25_CD ]_NN ,_, a_DT recent_JJ study_NN conducted_VBN in_IN an_DT 
        in_IN vitro_NN pharmacodynamic_JJ model_NN [_NN 28_CD ]_NN
        reported_VBD synergy_NN with_IN ceftazidime_NN for_IN 
        P_NN ._. aeruginosa_NN sensitive_JJ to_TO colistin_NN
        but_CC resistant_JJ to_TO other_JJ antibiotics_NNS ,_, including_VBG ceftazidime_NN ._.
        Synergy_NNP with_IN colistin_NN has_VBZ been_VBN reported_VBN for_IN
        trimethoprim-sulfamathoxazole_JJ (_( co-trimoxazole_JJ )_) [_NN 27_CD ]_NN and_CC
        rifampicin_NN [_NN 26_CD ]_NN ,_, but_CC no_DT patient_NN in_IN our_PRP$ study_NN received_VBD
        these_DT antibiotics_NNS ._.
        A_DT possible_JJ drawback_NN of_IN the_DT present_JJ study_NN is_VBZ the_DT use_NN of_IN
        the_DT disk_NN diffusion_NN method_NN for_IN testing_NN 
        in_IN vitro_NN susceptibility_NN to_TO colistin_NN ._.
        According_VBG to_TO a_DT recent_JJ study_NN [_NN 15_CD ]_NN ,_, this_DT approach_NN
        sometimes_RB yields_VBZ falsely_RB susceptible_JJ results_NNS ._. However_RB ,_,
        because_IN errors_NNS are_VBP observed_VBN mainly_RB for_IN 
        S_NNP ._. maltophilia_NN and_CC much_RB less_RBR often_RB
        for_IN 
        Acinetobacter_NNP spp_NN ._. ,_, it_PRP appears_VBZ
        unlikely_JJ that_IN the_DT use_NN of_IN a_DT different_JJ method_NN of_IN
        susceptibility_NN testing_NN would_MD materially_RB influence_VB our_PRP$
        findings_NNS ._.
        Toxicity_NNP ,_, particularly_RB nephrotoxicity_NN ,_, is_VBZ an_DT important_JJ
        concern_NN with_IN colistin_NN ._. In_IN the_DT study_NN conducted_VBN by_IN Koch-_NNP Weser_NNP
        and_CC coworkers_NNS [_NN 29_CD ]_NN ,_, impairment_NN in_IN renal_JJ function_NN -_:
        usually_RB reversible_JJ with_IN termination_NN of_IN treatment_NN -_: was_VBD
        observed_VBN in_IN 20_CD ._. 2_LS %_NN of_IN 288_CD patients_NNS ._. Levin_NNP and_CC coworkers_NNS [_NN 9_CD
        ]_NN also_RB reported_VBD a_DT high_JJ incidence_NN of_IN nephrotoxicity_NN (_( 37_CD %_NN )_) ,_,
        especially_RB in_IN patients_NNS who_WP already_RB had_VBD compromised_VBN renal_JJ
        function_NN [_NN 9_CD ]_NN ._. Because_IN most_JJS of_IN the_DT patients_NNS in_IN both_DT
        studies_NNS were_VBD seriously_RB ill_JJ ,_, it_PRP is_VBZ highly_RB probable_JJ that_IN at_IN
        least_JJS part_NN of_IN the_DT reported_VBN toxicity_NN was_VBD the_DT result_NN not_RB of_IN
        the_DT drug_NN but_CC of_IN the_DT disease_NN ._. On_IN the_DT other_JJ hand_NN ,_, experience_NN
        with_IN the_DT drug_NN in_IN patients_NNS with_IN cystic_JJ fibrosis_NNS ,_, has_VBZ shown_VBN
        only_RB minimal_JJ nephrotoxicity_NN [_NN 19_CD 20_CD 21_CD 30_CD ]_NN ._.
        Garnacho-_NNP Montero_NNP and_CC coworkers_NNS [_NN 12_CD ]_NN ,_, in_IN patients_NNS with_IN
        VAP_NNP ,_, observed_VBD that_IN there_EX was_VBD no_DT significant_JJ difference_NN in_IN
        development_NN of_IN renal_JJ failure_NN between_IN colistin_NN and_CC imipenem_NN ._.
        In_IN our_PRP$ study_NN ,_, despite_IN a_DT dosage_NN of_IN colistin_NN that_WDT was_VBD much_RB
        higher_JJR than_IN that_DT usually_RB reported_VBN ,_, nephrotoxicity_NN was_VBD
        moderate_JJ (_( 14_CD ._. 3_LS %_NN )_) and_CC it_PRP is_VBZ unlikely_JJ that_IN this_DT had_VBD a_DT
        clinically_RB significant_JJ impact_NN in_IN most_JJS cases_NNS ,_, although_IN the_DT
        drug_NN might_MD have_VB contributed_VBN to_TO the_DT poor_JJ outcome_NN of_IN patients_NNS
        under_IN CVVHD_NNP ._.
        Neurotoxicity_NNP and_CC neuromuscular_NN blockade_NN were_VBD also_RB
        reported_VBN with_IN colistin_NN in_IN the_DT 1960_CD s_VBZ [_NN 29_CD 31_CD ]_NN ,_, but_CC more_RBR
        recent_JJ studies_NNS did_VBD not_RB report_VB clinically_RB evident_JJ [_NN 9_CD 30_CD ]_NN
        or_CC neurophysiologic_JJ [_NN 12_CD ]_NN abnormalities_NNS ._. No_DT clinical_JJ
        neurotoxicity_NN was_VBD observed_VBN in_IN the_DT present_JJ study_NN ._.
      
      
        Conclusion_NNP
        Although_IN our_PRP$ findings_NNS with_IN colistin_NN can_MD be_VB considered_VBN
        encouraging_VBG in_IN comparison_NN with_IN previous_JJ experience_NN ,_, the_DT
        small_JJ number_NN of_IN patients_NNS ,_, the_DT concomitant_NN use_NN of_IN β-lactams_JJ ,_,
        and_CC the_DT absence_NN of_IN a_DT control_NN group_NN in_IN the_DT study_NN do_VBP not_RB
        allow_VB for_IN a_DT clear_JJ verdict_NN on_IN the_DT clinical_JJ effectiveness_NN of_IN
        colistin_NN ._. On_IN the_DT other_JJ hand_NN ,_, the_DT moderate_JJ incidence_NN of_IN
        complications_NNS suggests_VBZ that_DT colistin_NN may_MD be_VB a_DT relatively_RB
        safe_JJ choice_NN in_IN patients_NNS with_IN normal_JJ renal_JJ function_NN ,_, at_IN
        least_JJS when_WRB administered_VBN in_IN an_DT ICU_NNP with_IN proper_JJ monitoring_NN of_IN
        variables_NNS that_WDT affect_VBP renal_JJ function_NN ._. Pending_VBG a_DT randomized_JJ
        controlled_VBN trial_NN ,_, the_DT use_NN of_IN intravenous_JJ colistin_NN should_MD be_VB
        considered_VBN in_IN severe_JJ infections_NNS with_IN Gram-negative_NNP bacilli_NN
        when_WRB it_PRP remains_VBZ the_DT only_RB antibiotic_JJ to_TO which_WDT the_DT causative_JJ
        pathogen_NN is_VBZ sensitive_JJ 
        in_IN vitro_NN ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Key_JJ messages_NNS
        •_NN Intravenous_NNP colistin_NN is_VBZ not_RB associated_VBN with_IN
        prohibitive_JJ complications_NNS in_IN critically_RB ill_JJ patients_NNS ,_, even_RB
        when_WRB it_PRP is_VBZ administered_VBN at_IN doses_NNS higher_JJR than_IN are_VBP usually_RB
        reported_VBN
        •_NN Pending_VBG a_DT definitive_JJ randomized_JJ controlled_VBN trial_NN ,_, the_DT
        use_NN of_IN intravenous_JJ colistin_NN should_MD be_VB considered_VBN in_IN severe_JJ
        infections_NNS with_IN Gram-negative_NNP bacilli_NN when_WRB it_PRP remains_VBZ the_DT
        only_RB antibiotic_JJ to_TO which_WDT the_DT causative_JJ pathogen_NN is_VBZ
        sensitive_JJ 
        in_IN vitro_NN 
      
      
        Abbreviations_NNP
        APACHE_NNP =_SYM Acute_NNP Physiology_NNP and_CC Chronic_NNP Health_NNP Evaluation_NNP ;_:
        CVVHD_NNP =_SYM continuous_JJ venovenous_JJ hemodiafiltration_NN ;_: ICU_NNP =_SYM
        intensive_JJ care_NN unit_NN ;_: VAP_NNP =_SYM ventilator-associated_JJ
        pneumonia_NN ._.
      
    
  
